INTRODUCTION
Conventional preparation is usually administered two or three times a day, which will lead to large fluctuation in drug plasma concentration and side effects on human body. Constant plasma levels can offer a therapeutic advantage for many drugs in terms of both efficacy and tolerance of the treatment [1] . Once-daily controlled release formulations are often desirable. The osmotic pump tablet that holds a prominent place among controlled release systems has many advantages, such as reducing risk of adverse reactions, improving compliance of patients and exhibiting comparable in vitro/in vivo drug release. Pharmaceutical agents can be delivered in a controlled pattern over a long period by osmotic pressure; there has been increasing interest in the development of osmotic devices over the past two decades. Drug delivery from this system is not influenced by the different physiological factors within the gut lumen and the release characteristics can be predicted easily from the known properties of the drug and the dosage form [2] . The elementary osmotic pump (EOP) consists of an osmotic core, with the drug surrounded by a semipermeable membrane with a delivery orifice. In operation, the osmotic core acts by imbibing water from the surrounding medium via the
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Atenolol, also known as 4-[2-hydroxy-3-[(1-methylethyl) amino]propoxy]benzeneacetamide is a β-blocking agent, could effectively reduce systolic and diastolic blood pressures, and it is widely used alone or in combination to treat hypertension in a dose of 25-mg twice a day. Atenolol is commercially available as conventional tablet. The tablet is usually administered 25 mg two or three times a day, which would lead to large fluctuation in drug plasma concentration and side effect on human body. Controlled release systems are desirable to solve these problems. Among these, osmotic pump tablet offers several advantages, such as reducing risk of adverse reactions, improving compliance of patients and exhibiting comparable in vitro/ in vivo drug release The objective of the present study was to develop controlled porosity osmotic pump (CPOP) tablets of atenolol. Lactose:Fructose mixture was used as the osmogent. The tablets were coated with cellulose acetate as the semipermeable membrane containing sorbitol as a pore forming or channeling agent. The formulations were optimized by applying a full 3 2 factorial design and evaluated for in-vitro and in-vivo performance.
MATERIALS AND METHODS

Materials
Atenolol was obtained as a gift sample (Wockhardt Limited, Aurangabad), Fructose and Lactose as osmotic agent (Research fine lab, Mumbai) and microcrystalline cellulose as diluent. Cellulose acetate was employed as a semipermeable membrane (Shreya Life Sciences, Aurangabad), PEG 400 was used as a plasticizer (Thermofisher Scientific Ind Pvt. Ltd, Mumbai), Sorbitol as a pore former (Research fine lab, Mumbai). The atenolol conventional tablet of 50 mg strength (Zydus Cadila Ahmadabad) was used as the reference for comparison. Other chemicals used were of analytical grade.
Analytical method for estimation of Atenolol
Analysis of atenolol was done by UV-Spectrophotometric method at λmax 226.6 nm.
Preparation of core tablet
Tablets were prepared by wet granulation method; the granules were prepared by non-aqueous granulation technique compression was performed 8 mm punch using karnavti multi station tablet compression machine as per the composition in table-3.
Coating of core tablets
The core tablets were coated by using the coating composition as per the formula given in the Table- 
Drug content uniformity: (IP 2007)
Ten tablets were weighed and average weight was calculated. All tablets were crushed and powder equivalent to 0.1 g drug and dissolved in 250 ml volumetric flask using 150 ml of methanol the resulting suspension was heated to 60 0 C and shaken for 15 min cool, and dilute to 250 ml with methanol. Filter through a sintered glass funnel and dilute a suitable volume of filterate with sufficient methanol to produce a solution containing 0.01 % w/v of atenolol. Absorbance of solution was measured at the maximum at 275 nm.
Experimental design
Based on the primary batches factorial design was applied by varying the concentrtation of osmotic agent and pore former and its effects on drug release was studied. Osmotic agent was selected as one of the factor and pore former as other.
D-Optimal design was applied using the software DesignExpert software (Version: 8.0.7.1). Two Factors (Independent variables) were the concentration of osmotic agent (Latose:Fructose) and pore former(Sorbitol). 3 2 factorial design was applied and 9 different formulations were prepared and evaluated (Table-2 
Evaluation parameters
The tablets were evaluated for appearance, shape, uniformity of thickness, diameter, hardness: friability weigh and drug content uniformity.
Dissolution Studies
The release rate of atenolol from CPOP (n=3) was determined from all batches. Batches were evaluated by studying the release study for first 2 hr in 900 ml 0.1 N HCl as dissolution medium, then remaining 10 hrs in 900 ml dissolution medium of phosphate buffer pH 6.8 using USP type II (Paddle) dissolution apparatus (Electrolab TDT) with 50 rpm at 37°C ± 0.5°C. The samples (5 ml) were withdrawn every hour for 12 hrs. The withdrawn samples were replaced with fresh dissolution medium. The samples were filtered through whatman filter paper and analyzed spectrophotometrically (Shimadzu UV-1800, Japan) at 226.6 nm.
Scanning Electron Microscopy (SEM):
Coating membrane of formulation obtained before and after complete in-vitro dissolution of core contents were examined for their porous morphology by scanning electron microscope (SEM). Before dissolution, the tablets were cut with a sharp blade and coating membrane was taken out. This membrane was cleaned with dried cloth to remove any adherent particles and was used for SEM. Similarly, coating membrane was taken out from the tablets after 12 hr of dissolution study and was used for SEM. The coating membrane was carefully washed 3-4 times with water to remove any adherent solid particles. Coating membranes were dried at 45°C for 12 hours and stored between sheets of wax paper in a dessicator until examination.
The small pieces of coating membranes were placed on a spherical brass stub (12 mm diameter) with a double backed adhesive tape in such a way that the outer portion of coating membrane comes in front of electronic beam and was examined under scanning electron microscope.
Accelarated Stability Studies
On the basis of In vitro evaluation of all the primary batches for the various parameters, the batch F 5 formulations were packed in strips of 0.04 mm thick aluminum foil laminated with polyvinyl chloride (PVC) and stored in ICH certified stability chambers for the accelerated stability studies. The stability of the tablets was studied for the duration of 90 days at temperature 40 0 C ± 2 0 C and 75% ± 5% relative humidity.
In-vivo Study: (Pharmacokinetic study)
Protocol for animal study was approved by Institutional Animal Ethical Committee of YB Chavan College of Pharmacy Aurangabad with approval no. (CPCSEA/IAEC/ P' ceutics-15/2011-12/52).
In-vivo study was performed to estimate various pharmacokinetic parameters and comparison was made between conventional conventional marketed tablet and formulated CPOP tablet of atenolol in rabbit plasma using UV Spectroscopic method.
Animals
The study was carried out using adult male Albino rabbits (weight 1.5-2 kg) in two groups of three animals each (n=3). The animals were housed under standard condition with a 12 hr light/dark cycle with free access of water before study.
Recovery study
Atenolol stock solution (100µg/ml) was prepared in pH 6.8 phosphate buffer .Then working solutions were prepared by diluting the stock solution in pH 6.8 phosphate buffer.100 µl of these serial dilutions were transferred into 1.5 ml Eppendrof tubes and the solvent were evaporated to dryness. The resulted samples were then used to spike blank rabbit plasma (100 µl) and the procedure done as described in 7.5. Calibration curve at 2.5, 5 and 10 µg/ml atenolol in rat plasma was generated having regression coefficient 0.998.
Administration of tablets and collection of plasma
The rabbits were fasted with water access for 12 hr prior to initiation of study. Group-I was administered with 50 mg conventional marketed tablet of atenolol (ATEN-50) using applicator along with 5 ml of water. Group-II was administered with formulated CPOP 50 mg tablet of atenolol (F 5 formulation) in the similar manner. The blood samples were withdrawn from marginal ear vein of rabbit through a syringe with 24 gauge needle just before and at 1, 2, 4, 6, 8, 10 and 12 hr after dosing. Each time 1 ml of blood was withdrawn.
Sample extraction and analytical procedure
After collection the samples were subjected to centrifugation in micro centrifuge at 4000 rpm for 8 min to separate plasma, form this separated plasma 500 µl was taken and alkalify with 100 µl of 0.1N NaOH and vortex vigorously for 3 min using vortex mixture. Ethyl acetate (1 ml) was then added to the mixture and vortex again for 5 min to extract atenolol. The samples were centrifuged at 4000 rpm for 8 min to separate the organic layer. The organic layer was collected and evaporated to dryness at room temperature. The residue was reconstituted in 5 ml of pH 6.8 phosphate buffer, vortex-mixed for 1 min and analyzed at 226.6 nm using UV Spectrophotometer. Plasma atenolol concentrations were determined by ultraviolet spectroscopy (UV-1800 SHIMADZU UV SPECROPHOTOMETER). The detection wavelength was 226.6 nm and the solvent was pH 6.8 phosphate buffer.
Estimation of Parameters
The parameters like C max , t max , AUC, AUMC and mean residence time (MRT) were calculated by using MathCAD.
RESULTS AND DISCUSSION
The core tablet formulations were evaluated for various parameters and the results revealed as per table-4. Formulation F1 shows less release as compared to other batches because F1 contains fewer amounts of pore former and osmogent while F9 contains high concentration of pore former and osmogent hence it shows highest release amongst all other formulations. 
Surface Response Plot
Equation:
% Drug release(Y) = +84.14+5.63×A+4.01×b+3.11×A×b
Figure 2. Surface Response Curve
Surface response plot shows a positive coefficient to both the factors.
Effect of Concentration of Osmogent
From the release profile, it is clear that increase in the concentration of osmotic agent, greater the driving force and enhances the release of drug and thus had a direct effect on drug release.
Effect of Pore Forming Level
It is clearly evident that the level of sorbitol had a direct effect on drug release. As the level of pore former increases, the membrane becomes more porous after coming into contact with the aqueous environment, resulting in faster drug release. 3 indicates SEM image of coating membrane before dissolution it shows that there is no any evidence of pores formation where as Fig. 4 clearly indicates after coming in contact with dissolution medium pores were formed and predict the mechanism of controlled porosity osmotic tablet by pore formation.
In-Vivo Study (Pharmacokinetic Study) 
Accelarated Stability Studies
The stability of the tablet formulation (F 5) was studied for the duration of 90 days at temperature 40 0 C±2 0 C and 75%±5% relative humidity. The tablets was then evaluated for various parameters viz. thickness, hardness, and drug content and release studies. Following results were oberved. From Table 10 it can be seen that there is no change in the evaluation parameter of the tablet during the 3 month . Table  11 showed, that a slight decrease release of drug, but it is negligible. Hence, stability studied revealed that formulation F 5 may stable for 3 month.
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